11.04.2011 • News

Wacker Starts Constructing New Polysilicon Production Plant

On Friday, Wacker Chemie officially started construction work on a fully integrated polysilicon-production site in the U.S. The groundbreaking ceremony was attended by numerous representatives from politics, business and local government. Wacker's CEO Rudolf Staudigl and Tennessee Governor Bill Haslam broke the ground for the large-scale project. The production complex, with an annual capacity of 15,000 metric tons, is scheduled for completion by late 2013. The project is the single largest investment in Wacker's history and is expected to create around 650 new jobs in Cleveland, Tennessee.

As announced earlier, Wacker is also expanding its German facilities at Burghausen and Nünchritz. The total increase there will be 10,000 metric tons per year by 2012. As a result, Wacker's overall hyperpure polysilicon capacity will rise to 67,000 metric tons by 2014.

With this new site in Tennessee, Wacker said it wants to make sure they can keep the pace with the global growth they expect for hyperpure polysilcon. "This expansion is necessary to meet our customers' future needs for top-quality polysilicon to make high-efficiency solar cells," says Wacker's CEO Rudolf Staudigl, explaining the investment decision. According to Staudigl, virtually the entire output of the Tennessee site has been contractually secured for 2014.

 

Company

Logo:

Wacker Chemie

Hanns-Seidel-Platz 4
81737 Munich
Germany

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read